Sulphonylurea therapy over six years does not delay progression to diabetes

Sulphonylurea therapy over six years does not delay progression to diabetes

Opis bibliograficzny
Główni autorzy:	Herlihy, O, Morris, R, Karunakaran, S, Holman, R, Grp, F
Format:	Journal article
Wydane:	2000

Podobne zapisy

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
od: Cull, C, i wsp.
Wydane: (2000)

Reinforced healthy living advice over six years does not delay progression to diabetes
od: Dyson, P, i wsp.
Wydane: (2000)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
od: Matthews, DR, i wsp.
Wydane: (1998)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
od: Matthews, DR, i wsp.
Wydane: (1998)

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
od: Holman, R, i wsp.
Wydane: (1987)

Sulphonylureas and hypoglycaemia.
od: Ferner, R, i wsp.
Wydane: (1988)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
od: Eeley, E, i wsp.
Wydane: (1996)

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
od: Ryder, R, i wsp.
Wydane: (2016)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
od: André J. Scheen
Wydane: (2021-01-01)

Risk factors predicting progression of diabetic retinopathy over six years in 1579 NIDDM patients
od: Stratton, I, i wsp.
Wydane: (1996)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
od: Eeley, E, i wsp.
Wydane: (1996)

Conventional reinforced healthy living advice over three years does not delay transition to diabetes in subjects with raised fasting glucose levels.
od: Dyson, P, i wsp.
Wydane: (1997)

Possible prevention of type 2 diabetes with acarbose or metformin over three years
od: Citroen, H, i wsp.
Wydane: (2000)

Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS
od: Cull, C, i wsp.
Wydane: (1999)

New uses for old drugs: neonatal diabetes and sulphonylureas.
od: Ashcroft, F
Wydane: (2010)

Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor
od: Peter Proks
Wydane: (2013-06-01)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
od: Rachman, J, i wsp.
Wydane: (1996)

Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes.
od: Woodcock, A, i wsp.
Wydane: (2007)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
od: Misra, S, i wsp.
Wydane: (2018)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
od: Pearson, E, i wsp.
Wydane: (2007)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
od: Huri, H.Z., i wsp.
Wydane: (2010)

Sulphonylureas and the rise and fall of beta-cell function
od: Matthews, DR, i wsp.
Wydane: (2005)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
od: Turner, R, i wsp.
Wydane: (1999)

The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
od: Karunakaran, S, i wsp.
Wydane: (1997)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
od: Rashida Vasanwala MD (Paeds), MRCPCH (UK), i wsp.
Wydane: (2010-06-01)

Phentolamine block of ATP-sensitive K+ channels does not involve interaction with the sulphonylurea receptor, SUR1.
od: Proks, P, i wsp.
Wydane: (1997)

Interactions between nicorandil and sulphonylureas: a structural basis.
od: Reimann, F, i wsp.
Wydane: (2001)

Sulphonylurea responsive monogenic diabetes in an Insulin treated 8 - year old child in West Africa; of more than academic interest and one of many?
od: Corley L, i wsp.
Wydane: (2021-03-01)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
od: Turner, R, i wsp.
Wydane: (1998)

Microvascular and macrovascular disease in subjects with increased but not diabetic fasting glucose levels
od: Karunakaran, S, i wsp.
Wydane: (1996)

Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
od: Ammälä, C, i wsp.
Wydane: (1996)

Homozygous hypomorphic HNF1A alleles are a novel cause of young-onset diabetes and result in sulphonylurea sensitive diabetes
od: Misra, S, i wsp.
Wydane: (2020)

Effects of protein phosphorylation on the sulphonylurea receptor of the pancreatic beta-cell.
od: Niki, I, i wsp.
Wydane: (1997)

Binding of sulphonylureas to plasma proteins – a KATP channel perspective
od: Proks, P, i wsp.
Wydane: (2018)

Alternative MDR splicing is required for direct potentiation of exocytosis by sulphonylureas
od: Wendt, A, i wsp.
Wydane: (2001)

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
od: Peter Proks, i wsp.
Wydane: (2018-01-01)

Successful transition to sulphonylurea therapy from insulin in a child with permanent neonatal diabetes due to a KCNJ11 gene mutation
od: Venkatesan Radha, i wsp.
Wydane: (2018-01-01)

RANDOMIZED CONTROLLED TRIAL OF SULFONYLUREA THERAPY IN 227 SUBJECTS WITH PERSISTENT FASTING HYPERGLYCEMIA
od: Karunakaran, S, i wsp.
Wydane: (1995)

A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
od: Proks, P, i wsp.
Wydane: (2006)

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
od: Hansen, A, i wsp.
Wydane: (2002)